ADIAL PHARMACEUTICALS, INC.
Business
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04, an investigational ondansetron-based therapeutic for alcohol use disorder in genetically targeted populations. The company's lead product candidate is undergoing Phase 3 clinical development following a Phase 3 ONWARD trial that showed efficacy in biomarker-positive heavy drinking patients. Adial pursues a pharmacogenetic strategy using a companion genetic diagnostic to identify patients most likely to benefit, with development focused on U.S. regulatory approval and potential European partnerships.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 3 | — | 3 | 1 | 2 | |
| General and administrative | 5 | — | 5 | 6 | 9 | |
| Total Operating Expenses | 8 | — | 8 | 7 | 11 | |
| Loss From Operations | −8 | — | −8 | −7 | −11 | |
| Interest income | 149,567 | — | 178,659 | 69,779 | 63,338 | |
| Inducement expense | — | — | −4 | — | — | |
| Loss on equity method investment | −492,130 | 492,130 | −552,183 | −193,884 | — | |
| Other income (expense) | 164,854 | — | −75,043 | 10,162 | — | |
| Total other Income (Expense) | −177,709 | — | −5 | −113,943 | 63,338 | |
| Net Loss | −8 | — | −13 | −5 | −13 | |
| Loss per share, basic (in Dollars per share) | −11.93 | — | −68.01 | −3.6 | −12.71 | |
| Loss per share, diluted (in Dollars per share) | −11.93 | — | −68.01 | −3.6 | −12.71 | |
| Weighted average shares, basic (in Shares) | 668,630 | — | 194,059 | — | 25 | |
| Weighted average shares, diluted (in Shares) | 668,630 | — | 194,059 | 1 | 1 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6 | 4 | 3 | 4 | 6 | |
| Prepaid expenses and other current assets | 299,666 | 308,239 | 371,597 | 349,441 | 389,501 | |
| Total Current Assets | 6 | 4 | 3 | 5 | 6 | |
| Intangible assets, net | 2,784 | 3,348 | 3,913 | — | — | |
| Equity method investment | 489,700 | 981,830 | 2 | — | — | |
| Total Assets | 7 | 5 | 5 | 6 | 7 | |
| Accounts payable | 655,207 | 250,130 | 103,325 | 276,410 | 286,192 | |
| Accrued expenses | 741,702 | 677,456 | 477,747 | 963,327 | 2 | |
| Total Current Liabilities | 1 | 975,858 | 653,076 | 2 | 3 | |
| Total Liabilities | 1 | 975,858 | 653,076 | 2 | 4 | |
| Commitments and contingencies see Note 8 | — | — | — | — | — | |
| Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 1,111,124 and 258,940 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,111 | 259 | 1,663 | 1,067 | 20,947 | |
| Additional paid in capital | 95 | 86 | 73 | 67 | 54 | |
| Accumulated deficit | −90 | −82 | −69 | −64 | −51 | |
| Total Stockholders Equity | 5 | 4 | 4 | 3 | 4 | |
| Total Liabilities and Stockholders Equity | 7 | 5 | 5 | 6 | 7 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 676,200 | 796,831 | 2 | 3 | 4 | |
| Amortization of intangible assets | 565 | 565 | 564 | 564 | 565 | |
| Cost of commitment shares issued | — | 74,999 | 51,901 | — | — | |
| Change in fair value contingent consideration | −150,000 | — | — | — | — | |
| Prepaid expenses and other current assets | 8,572 | 63,358 | −22,156 | 40,060 | 112,188 | |
| Accrued expenses | 100,296 | 199,709 | −485,580 | −1 | 2 | |
| Accrued expenses, related party | — | −47,942 | — | — | — | |
| Accounts payable and other current liabilities | 405,077 | 146,805 | −183,473 | — | — | |
| Accounts payable, related party | −48,272 | 24,210 | — | — | — | |
| Net cash used in operating activities | −6 | −7 | −7 | −11 | −12 | |
| Cash receipt from contingent consideration | 150,000 | — | — | — | — | |
| Net cash provided by investing activities | 150,000 | — | 2 | — | −34,016 | |
| Net proceeds from sale of common stock | 4 | 4 | 749,943 | 9 | 12 | |
| Proceeds from warrant exercise, net of expenses | 5 | 4 | 503 | 1,865 | 1 | |
| Net cash provided by financing activities | 8 | 8 | 4 | 9 | 14 | |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 2 | 923,443 | −1 | −2 | 2 | |
| Issuance of common stock to settle bonus accrual | 36,050 | — | — | — | 1 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ADIAL PHARMACEUTICALS, INC.'s CIK number?
ADIAL PHARMACEUTICALS, INC.'s SEC CIK number is 0001513525 (1513525). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ADIAL PHARMACEUTICALS, INC.'s SEC filings?
All of ADIAL PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ADIAL PHARMACEUTICALS, INC. last report earnings?
ADIAL PHARMACEUTICALS, INC. (ADIL) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-054219). This is ADIAL PHARMACEUTICALS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ADIAL PHARMACEUTICALS, INC.'s most recent earnings 8-K?
ADIAL PHARMACEUTICALS, INC.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001213900-26-054219. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ADIAL PHARMACEUTICALS, INC.'s latest earnings 8-K →
Look up any company's CIK number →